Literature DB >> 1088604

Solid-phase immunoradiometric assay of factor-VIII protein.

R B Counts.   

Abstract

A solid phase immunoradiometric assay for factor-VIII protein has been developed using 125I-labelled rabbit antibody made against highly purified factor VIII. Antibody specific for high molecular weight factor-VIII protein was isolated using an immunoadsorbent consisting of highly purified factor VIII bound to diazotized m-aminobenzyl (oxymethyl)-cellulose. The purified anti-factor VIII antibody was labelled with 125I while bound to the immunoadsorbent and then eluted at pH 2.9. Dilutions of plasma samples for assay were incubated for 48 h in anti-factor VIII antibody-coated tubes. The tubes were washed to remove unbound proteins and the 125I-labelled, purified antibody was added. After 48 h incubation the tubes were washed to remove unbound antibody and counted. The concentration of immunoreactive factor-VIII protein in pooled normal human plasma was determined to be 8 microgram/ml. The minimum amount of factor VIII measured by the assay is less than 0.16 ng. Factor-VIII protein was present in normal concentration in haemophilia A plasma, and in reduced concentration in von Willebrand's disease plasma. The method has the advantages of improved sensitivity, specificity, efficiency and economy as compared with previous factor-VIII immunoassays.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1088604     DOI: 10.1111/j.1365-2141.1975.tb00878.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  ADP-dependent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets.

Authors:  S Timmons; M Kloczewiak; J Hawiger
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

2.  Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.

Authors:  R B Counts; S L Paskell; S K Elgee
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

3.  [Problems of conductor demonstration in haemophilia A: error possibilities in the determination of factor-VIII-associated antigen].

Authors:  B Salfner; U Göbel; H Kokemohr; H Voss; C Petrich
Journal:  Blut       Date:  1977-04

4.  Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

Authors:  M J Weinstein; L E Chute
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

5.  Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.

Authors:  M Weinstein; L Chute; D Deykin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

6.  Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow.

Authors:  T M Wick; J L Moake; M M Udden; S G Eskin; D A Sears; L V McIntire
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

7.  Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

Authors:  A R Thompson
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.